MediGene Obtains European Patent on EndoTAG(TM)-1
MediGene has exclusively licensed the patent no. EP 1 210 065 from the University of California, San Francisco. Further patent applications regarding the manufacturing process and administration of the drug have also been filed by MediGene AG. In addition, MediGene holds several patents on the EndoTAG(TM) technology in general.
EndoTAG(TM) aims at a novel method of cancer therapy by "starving out" tumors. EndoTAG(TM)-1 combines the established active substance Paclitaxel with a carrier system of positively charged lipid complexes. They allow a transport of the substance specifically to the negatively charged newly developed tumor blood vessels. There the drug is discharged in order to destroy the blood vessels, thus suppressing the tumor's nutrient supply. MediGene is currently conducting an extensive clinical phase II trial of EndoTAG(TM)-1 for the treatment of pancreatic cancer. Another clinical phase II trial in the indication hormone-resistant breast cancer is about to start in the near future. Apart from that, MediGene is also examining the application of the EndoTAG(TM) technology for the treatment of other diseases.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.